Macromolecular prodrugs of 5-fluorouracil. 2: Enzymatic degradation

Journal of Controlled Release

Volumn 39, Issue 1, 1996, Pages 79-92

  Nichifor, Marieta ^a   Schacht, Etienne H ^a   Seymour, Leonard W ^b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

5 Fluorouracil; Cathepsin; Collagenase; Lysosomal enzyme; Prodrug

Indexed keywords

2 (5 FLUOROURACIL 1 YL) GLYCINE ETHYL ETHER; 4 NITROPHENYL CHLOROFORMATE; CATHEPSIN B; CATHEPSIN D; COLLAGENASE; DEXTRAN T70; FLUOROURACIL; FLUOROURACIL DERIVATIVE; LYSOSOME ENZYME; MACROGOL; OLIGOPEPTIDE; POLYMER; POLY[N5 (3 HYDROXYPROPYL)GLUTAMINE]; PRODRUG; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG DEGRADATION; DRUG RELEASE; HYDROLYSIS; MACROMOLECULE; PRIORITY JOURNAL;

EID: 0029877192     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00141-7     Document Type: Article

References (55)

1. C.R. Gardner, Potential and limitations of drug targeting: an overview, Biomaterials 6 (1985) 153-160.
2. H. Jatzkevitz, A peptamine (glycyl-L-leucylmescaline) bound to a colloidal blood plasma substitute (polyvinylpyrrolidone) as a new type of depot for a biologically active primary amine, Z. Naturforsch. 10B (1955) 27-31.
3. W.A.R. Van Heeswijk, C.J.T. Hoes, T. Stoffer, M.J.D. Eeninj, W. Potman and J. Feijen, The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin, J. Control. Release 1 (1985) 301-315.
4. R. Duncan, I.C. Hume, H.J. Yardley, P.A. Flanagan, K. Ulbrich, V. Subr and J. Strohalm, Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers, J. Control. Release 16 (1991) 121-136.
5. K. Ulbrich, J. Strohalm and J. Kopecek, Polymers containing enzymatically degradable bonds. 3. Poly[N-(2-hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable by trypsin, Makromol. Chem. 182 (1981) 1917-1928.
6. J. Kopecek, P. Rejmanova and V. Chytrý, Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide, Makromol. Chem. 182 (1981) 799-809.
7. P. Rejmanova, B. Obereigner and J. Kopecek, Polymers containing enzymatically degradable bonds. 2. Poly[N-(2-hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable by chymotrypsin, Makromol. Chem. 182 (1981) 1899-1915.
8. M. Móra and J. Pató, Effect of negative electric charges of polymers on the chymotrypsin catalyzed hydrolysis of the side chains, J. Control. Release 18 (1992) 153-158.
9. A. Trouet, M. Masquelier, R. Baurain and D. Deprez-De Campeneere, A covalent linkage between daunomycin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies, Proc. Natl. Acad. Sci. USA 79 (1982) 626-629.
10. R. Duncan, H. Cable, J. Lloyd, P. Rejmanova and J. Kopecek, Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes, Makromol. Chem. 184 (1983) 1997-2008.
11. R. Duncan, L.W. Seymour, K. Ulbrich and J. Kopecek, Soluble synthetic polymers for targeting and controlled release of anticancer agents, particularly anthracycline antibiotics, J. Bioact. Comp. Polym. 3 (1988) 4-15.
12. A. De Marre, L.W. Seymour and E. Schacht, Evaluation of the hydrolytic and enzymatic stability of macromolecular mitomycin C derivatives, J. Control. Release 31 (1994) 89-97.
13. C. De Duve, Lysosomes, a new group of cytoplasmic particles, in: T. Hayashi (Ed.), Subcellular Particles, Ronald Press, New York, 1959, pp 128-159.
14. L.A. Liotta, N.C. Rao and U.M. Wewer, Biochemical interactions of tumor cells with basement membrane, Annu. Rev. Biochem. 55 (1986) 1037-1057.
15. K. Tryggvason, M. Hoyhtya and M. Saho, Proteolytic degradation of extracellular matrix in tumor invasion, Biochim. Biophys. Acta 907 (1987) 191-217.
16. R. Canete-Soler, L. Litzky, I. Lubesky and R.J. Muschel, Localization of the 92 kD gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization, Am. J. Pathol. 144 (1994) 518-527.
17. M.S. Naylor, G.W. Stamp, B.D. Davies and F.R. Balkwill, Expression and activity of MMPs and their regulators in ovarian cancer, Int. J. Cancer 58 (1994) 50-56.
18. L. David, J.M. Nesland, R. Holm and M. Sobrinho-Simoes, Expression of laminin, collagen IV, fibronectin and type IV collagenase in gastric carcinoma, Cancer 73 (1994) 518-527.
19. J. Milburn Jessup, Cathepsin B and other proteases in human colorectal carcinoma, Am. J. Pathol. 145 (1994) 253-262.
20. E. Campo, J. Munoz, R. Miquel, A. Palacin, A. Cardesa, B.F. Sloane and M.R. Emmert-Buck, Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival, Am. J. Pathol. 145 (1994) 301-309.
21. E. Weber, D. Günther, F. Laube, B. Wiederanders and H. Kirschke, Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumor growth, J. Cancer Res. Clin. Oncol. 120 (1994) 564-567.
22. E. Liaudet, M. Garcia and H. Rochefort, Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal, Oncogene 9 (1994) 1145-1154.
23. T. Funahashi, M. Shimamura, T. Kocha, T. Fukuda and T. Aoyagi, Proportionality of protease activities in malignant cells to their metastatic potentials, Biol. Pharm. Bull. 17 (1994) 1118-1120.
24. T.L. Moser, T.N. Young, G.C. Rodriguez, S.V. Pizzo, R.C. Bast and M. Sharon Stack, Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma, Int. J. Cancer 56 (1994) 552-559.
25. J.-D. Vassalli and M.S. Pepper, Membrane proteases in focus, Nature 370 (1994) 14-16.
26. J.-I. Yamashita, M. Ogawa, S. Ikei, H. Omachi, S.-I. Yamashita, T. Saishoji, K. Nomura and H. Sato, Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer, Br. J. Cancer 69 (1994) 72-76.
27. J.A. Uría, A.A. Ferrando, G. Velasco, J.M.P. Freije and C. López-Otín, Structure and expression in breast tumors of human TIMP-3, a new member of the metallopronase inhibitor family, Cancer Res. 54 (1994) 2091-2094.
28. D.W. Visscher, M. Hoyhtya, S.K. Ottosen, C.-M. Liang, F.H. Sarkar, J.D. Crissman and R. Fridman, Int. J. Cancer 59 (1994) 339-344.
29. P. Calabresi and R.E. Parks, Jr, Antimetabolites, in: L.S. Goodman, T.W. Raal and F. Murad (Eds), Pharmacological Basis of Therapeutics, McMillan, New York, 1985, pp. 1268-1276.
30. M. Akashi and K. Takemoto, New aspects of polymer drugs, Adv. Polym. Sci. 97 (1990) 108-146.
31. T. Ouchi, A. Fujino, K. Tanaka and Y. Banba, Synthesis and antitumor activity of conjugates of poly(α-malic acid) and 5-fluorouracil bound via ester, amide or carbamoyl bonds, J. Control. Release 12 (1990) 143-153.
32. T. Ouchi, Y. Hagihara, K. Takahashi, Y. Takano and I. Igarashi, Synthesis and anti-tumor activity of poly(ethylene glycol)s linked to 5-fluorouracil via urethane or urea bonds, Drug Des. Discovery, 9 (1992) 93-105.
33. T. Ouchi, T. Banba, T. Matsumoto, S. Suzuki and M. Suzuki, Synthesis and anti-tumor activity of conjugates of 5-fluorouracil and chito-oligosaccharides involving a hexamethylene spacer group and carbamoyl bonds, Drug Des. Delivery, 6 (1990) 281-287.
34. M. Nichifor and S. Schacht, Synthesis of peptide derivatives of 5-fluorouracil, Tetrahedron 50 (1994) 3747-3760.
35. M. Nichifor and E. Schacht, Synthesis of diastereomerically pure oligopeptide derivatives of 5-fluorouracil, Tetrahedron Lett. (1995) submitted.
36. M. Nichifor and E. Schacht, Chemical and enzymatic hydrolysis of 5-fluorouracil prodrugs. 1. Dipeptide derivatives, Int. J. Pharm. (1995) submitted.
37. W.D. Kingsburry, J.C. Boehm, R.J. Mehta, S.F. Grappel and Ch. Gilvarg, A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil, J. Med. Chem. 27 (1984) 1447-1451.
38. M. Nichifor, V. Coessens and E. Schacht, Macromolecular prodrugs of 5-fluorouracil. 1. Synthesis and hydrolytic stability, J. Bioact. Comp. Polym. 10 (1995) 199-222.
39. A. De Marre, H. Soyez and E. Schacht, Synthesis of macromolecular mitomycin C derivatives, J. Control. Release 32 (1994) 129-137.
40. A. Trouet, Isolation of rat liver lysosomal enzymes, Methods Enzymol. 31 (1974) 323-330.
41. A.H. Boag and I.D. Young, Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma, Am. J. Pathol. 144 (1994) 585-591.
42. M.S. Stack and R.D. Gray, Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide, J. Biol. Chem. 264 (1989) 4277-4281.
43. W. Bode, P. Reinemer, R. Huber, T. Kleine, S. Schnierer and H. Tschesche, The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity, EMBO J. 13 (1994) 1263-1269.
44. H. Nagase, C.G. Fields and G.B. Fields, Design and characterization of a fluorogenic substrate selectively hydrolysed by stromelysin 1 (MMP-3), J. Biol. Chem. 269 (1994) 20952-20957.
45. A. Taylor, Aminopeptidases: structure and function, FASEB J. 7 (1993) 290-298.
46. T. Ohta, T. Terada, T. Nagakawa, H. Tajima, H. Itoh, L. Fonseca and I. Miyazaki, Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastasis, Br. J. Cancer 69 (1994) 152-156.
47. M.R. Buck, D.G. Karustis, N.A. Day, K.V. Honn and B.F. Sloane, Degradation of extracellular matrix proteins by human cathepsin B from normal and tumor tissues, Biochem. J. 282 (1992) 273-278.
48. H. Kobayashi, M. Schmitt, L. Goretzki, N. Chucholowski, J. Calvete, M. Kramer, W.A. Güntzler, F. Jänicke and H. Graeff, Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA), J. Biol. Chem. 266 (1991) 5147-5152.
49. A.J. Barrett and H. Kirschke, Cathepsin B, Cathepsin H, and Cathepsin L, Methods Enzymol. 80 (1981) 535-561.
50. N. Marks, M.J. Berg, L.-M. Chi, J. Choi, R. Durrie, J. Swistok, R.C. Makofske, W. Danho and V.S. Sapirstein, Hydrolysis of amyloid precursor protein-derived peptides by cysteine proteinases and extracts of rat brain clathrin-coated vesicles, Peptides 15 (1994) 175-182.
51. P. Rejmanova, J. Kopecek, J. Pohl, M. Baudys and V. Kosta, Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B, Makromol. Chem. 184 (1983) 2009-2020.
52. J. Kopecek, P. Rejmanova, R. Duncan and J.B. Lloyd, Controlled release of drug model from N-(2-hydroxypropyl)methacrylamide copolymers, Ann. NY Acad. Sci. 446 (1985) 93-104.
53. R. Duncan, P. Rejmanova-Kopeckova, J. Strohalm, I. Hume, H.C. Cable, J. Pohl, J.B. Lloyd and J. Kopecek, Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro, Br. J. Cancer 55 (1987) 165-174.
54. L.W. Seymour, K. Ulbrich, P.S. Steyger, M. Brereton, V. Subr, J. Stromalm and R. Duncan, Tumoritropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma, Br. J. Cancer 70 (1994) 636-641.
55. 6 toward human hepatocarcinoma cell line targeted with galactosamine and to mouse splenocytes targeted with antibodies, J. Control. Release 25 (1993) 71.